Health Care Stocks On The Rise With Help From 5 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,456 as of Friday, Jan. 3, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,718 issues advancing vs. 1,181 declining with 172 unchanged.

The Health Care sector currently sits up 0.4% versus the S&P 500, which is unchanged. Top gainers within the sector include Agilent Technologies ( A), up 1.5%, Bristol-Myers Squibb Company ( BMY), up 1.2%, Novo Nordisk A/S ( NVO), up 1.2%, Allergan ( AGN), up 1.1% and Johnson & Johnson ( JNJ), up 0.8%. On the negative front, top decliners within the sector include Herbalife ( HLF), down 5.3%, Biogen Idec ( BIIB), down 1.6%, Celgene Corporation ( CELG), down 1.3%, Amgen ( AMGN), down 1.1% and Gilead ( GILD), down 1.0%.

TheStreet would like to highlight 5 stocks pushing the sector higher today:

5. Covidien ( COV) is one of the companies pushing the Health Care sector higher today. As of noon trading, Covidien is up $0.52 (0.8%) to $67.94 on light volume. Thus far, 325,400 shares of Covidien exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $67.30-$67.97 after having opened the day at $67.48 as compared to the previous trading day's close of $67.42.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $30.8 billion and is part of the health services industry. Shares are unchanged year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, HCA Holdings ( HCA) is up $0.77 (1.6%) to $48.54 on light volume. Thus far, 831,782 shares of HCA Holdings exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $47.83-$48.68 after having opened the day at $47.94 as compared to the previous trading day's close of $47.77.

HCA Holdings, Inc., through its subsidiaries, provides health care services in the United States. HCA Holdings has a market cap of $21.4 billion and is part of the health services industry. Shares are up 0.1% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates HCA Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and poor profit margins. Get the full HCA Holdings Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Thermo Fisher Scientific ( TMO) is up $0.67 (0.6%) to $110.30 on light volume. Thus far, 345,290 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $109.67-$110.48 after having opened the day at $109.96 as compared to the previous trading day's close of $109.63.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $40.2 billion and is part of the health services industry. Shares are down 1.5% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Thermo Fisher Scientific Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Medtronic ( MDT) is up $0.76 (1.3%) to $58.00 on heavy volume. Thus far, 5.5 million shares of Medtronic exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $57.70-$58.20 after having opened the day at $58.20 as compared to the previous trading day's close of $57.24.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company operates in two segments, Cardiac and Vascular Group, and Restorative Therapies Group. Medtronic has a market cap of $57.3 billion and is part of the health services industry. Shares are down 0.3% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Medtronic a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Medtronic Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, UnitedHealth Group ( UNH) is up $0.73 (1.0%) to $75.30 on light volume. Thus far, 1.3 million shares of UnitedHealth Group exchanged hands as compared to its average daily volume of 5.1 million shares. The stock has ranged in price between $74.60-$75.76 after having opened the day at $74.80 as compared to the previous trading day's close of $74.57.

UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. UnitedHealth Group has a market cap of $75.8 billion and is part of the health services industry. Shares are down 1.0% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate UnitedHealth Group a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates UnitedHealth Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full UnitedHealth Group Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

Dow Posts First Gain in Nine Sessions; Oil Jumps

Dow Posts First Gain in Nine Sessions; Oil Jumps